FDA grants orphan drug status for Neurocrine’s NBI-77860 to treat CAH
NBI-77860 is a potent, selective non-peptide CRF receptor antagonist as showed in a range of in vitro/in vivo assays and human clinical trials. Blockade of CRF receptors at
XtalPi has entered a strategic partnership valued at more than $400m with an international biopharmaceutical company to develop oral small-molecule therapeutics targeting a G protein-coupled receptor (GPCR).
Speaking ahead of the eyeforpharma Barcelona 2015 conference, Alberto Grua, CCO at Grünenthalechoed similar industry commitments to putting patient’s needs to the forefront of their decision making, and
A provisional patent application is a legal document which establishes an early priority date for the benefit of claiming "first to file" status against other companies or individuals